Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05493280 · ClinicalTrials.gov registry record · NA

Fractionated 1927nm Laser for Hyperpigmentation in Fitzpatrick Skin Phototypes V and VI

A NA study of Hyperpigmentation, sponsored by University of Texas Southwestern Medical Center.

Completed
Registry status
NA
Development phase
15
Enrollment target
1
Study location

NCT05493280: Completed NA study of Hyperpigmentation, sponsored by University of Texas Southwestern Medical Center.

NCT05493280 is a NA study of Hyperpigmentation that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 15 participants, below the 33-participant average among 5 other Hyperpigmentation trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05493280, a NA study of Hyperpigmentation, has completed, sponsored by University of Texas Southwestern Medical Center.

COMPLETED
Registry status
NA
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this study is to assess the efficacy of 1927nm non-ablative fractionated laser therapy to treat hyperpigmentation in patients ages 18-75 with Fitzpatrick Skin Phototypes V and VI and explore an effective, adjunctive pre- and post-procedural regimen to prevent iatrogenic dyspigmentation or scarring in this population.

Primary Outcome

Quantitively assessment of change in overall spots using measurements provided VISIA 3D analysis of front face Count- the number of individual features detected in the region of interest.

Conditions Studied

Interventions

  • DEVICE MOXI

Study Locations (1)

Texas

  • UT Southwestern Medical Center- Dept of Plastic Surgery - Dallas

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2022-11-14
Est. Completion 2024-12-31
Phase NA

What the finished NCT05493280 record still lists

NCT05493280 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 33-participant average among 5 other Hyperpigmentation trials with a reported enrollment target (55% lower).

The record links to 1 condition, with Hyperpigmentation appearing as the primary indexed condition, and to 1 intervention - of which MOXI is the first listed.

NCT05493280 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT05493280 about?

NCT05493280 is a clinical study titled "Fractionated 1927nm Laser for Hyperpigmentation in Fitzpatrick Skin Phototypes V and VI". The primary objective of this study is to assess the efficacy of 1927nm non-ablative fractionated laser therapy to treat hyperpigmentation in patients ages 18-75 with Fitzpatrick Skin Phototypes V and VI and explore an effective, adjunctive pre- and post-procedural regimen to prevent iatrogenic dysp...

What is the current status of trial NCT05493280?

This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2022-11-14. Estimated completion is 2024-12-31.

What conditions does trial NCT05493280 study?

This clinical trial studies the following conditions: Hyperpigmentation.

What interventions are being tested in trial NCT05493280?

The interventions under investigation include: MOXI (DEVICE).

Who is sponsoring clinical trial NCT05493280?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05493280 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hyperpigmentation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05493280, the US trial registry maintained by the National Library of Medicine. NCT05493280 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.